Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference
Rhea-AI Summary
Turning Point Therapeutics (NASDAQ: TPTX) announced that President and CEO Athena Countouriotis will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference. The session is scheduled for March 8, 2022, from 11:10 a.m. to 11:40 a.m. ET, accessible via webcast on their investor page. The company focuses on precision oncology, developing therapies targeting genetic drivers of cancer, with key candidates including repotrectinib for non-small cell lung cancer and several others in its pipeline.
Positive
- None.
Negative
- None.
News Market Reaction – TPTX
In the trading session that priced this news, TPTX declined 2.18%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference.
Dr. Countouriotis’ session is scheduled to take place on Tuesday, March 8 from 11:10 a.m. to 11:40 a.m. ET. The session will be accessible via webcast through the Investors page of www.tptherapeutics.com.
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Contact:
Adam Levy
ir@tptherapeutics.com
858-867-6366
